Covalent ligand discovery platform
Oncology drug discovery platform
A drug discovery engine that pairs covalent chemistry across all nucleophilic amino acid residues with chemical biology and cancer biology to generate small-molecule candidates against targets without conventional binding pockets, including intrinsically disordered proteins, scaffolding proteins, transcription factors, paralogs and protein-protein interfaces.
- Covalent ligand discovery across all nucleophilic amino acids
- Targets intrinsically disordered proteins, scaffolding proteins and transcription factors
- Captures shallow, challenging and transient binding pockets
- Paralog-selective and protein-protein interface targeting
- Integrated chemical biology, cancer biology and medicinal chemistry
Built for
Cancer patients who lack meaningful therapies, reached via pharmaceutical partners and, ultimately, oncologists prescribing approved medicines